Content: publishing "SPLOPBAN"

content/news/2022-07-15-SPLOPBAN.md

@@ -4,6 +4,7 @@ authors = ["Ed Mahon"]
 blurb = "A federal lawsuit alleges the Pennsylvania court system discriminated against people with opioid use disorder, raising questions about who is responsible for decisions made by local judges."
 byline = "Ed Mahon of Spotlight PA"
 description = "A federal lawsuit alleges the Pennsylvania court system discriminated against people with opioid use disorder, raising questions about who is responsible for decisions made by local judges."
+feed-exclude = false
 image = "external/0xw0tndqfe9xz56gcxmj1ev4wc.jpeg"
 image-credit = "Kent M. Wilhelm / Spotlight PA"
 image-description = "The Justice Department sued the Pennsylvania court system in February, alleging that it discriminated against people with opioid use disorder."
@@ -12,6 +13,7 @@ internal-id = "SPLOPBAN"
 kicker = "Health"
 modal-exclude = false
 no-index = false
+pinned = false
 published = 2022-07-15T05:00:35-04:00
 slug = "pa-court-lawsuit-opioid-medication-discrimination"
 suppress-date = false
@@ -39,7 +41,7 @@ Three drugs — methadone, buprenorphine, and extended-release naltrexone — ar
 
 For people with opioid use disorder, buprenorphine and methadone can reduce withdrawal symptoms and cravings without causing a euphoric high, according to a report from the <a href="https://web.archive.org/20220718064806/https://nida.nih.gov/download/21349/medications-to-treat-opioid-use-disorder-research-report.pdf?v=99088f7584dac93ddcfa98648065bfbe">National Institute on Drug Abuse</a>, a federal agency. The medications allow patients to “function normally, attend school or work, and participate in other forms of treatment,” the report says.
 
-The third drug, naltrexone, works to block the euphoric effects of opioid drugs, and the federal <a href="https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/naltrexone">Substance Abuse and Mental Health Services Administration has found t</a>here is “no abuse and diversion potential with naltrexone.”
+The third drug, naltrexone, works to block the euphoric effects of opioid drugs, and the federal <a href="https://web.archive.org/20200908202747/https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/naltrexone">Substance Abuse and Mental Health Services Administration has found t</a>here is “no abuse and diversion potential with naltrexone.”
 
 ## What does the Department of Justice allege?